Brokerages Set iTeos Therapeutics, Inc. (NASDAQ:ITOS) PT at $15.86

Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) have received a consensus recommendation of “Hold” from the seven research firms that are currently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $15.86.

Several brokerages have recently weighed in on ITOS. Leerink Partners reaffirmed a “market perform” rating and issued a $9.00 target price (down previously from $47.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Raymond James Financial set a $12.00 price objective on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Leerink Partnrs cut shares of iTeos Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 14th. Wells Fargo & Company restated an “equal weight” rating and set a $12.00 target price (down previously from $13.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 28th. Finally, Wedbush cut shares of iTeos Therapeutics from an “outperform” rating to a “neutral” rating and lifted their target price for the stock from $10.00 to $12.00 in a research report on Wednesday, May 28th.

Insider Activity

In other news, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the business’s stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total value of $5,079,339.46. Following the completion of the transaction, the insider owned 2,108,594 shares of the company’s stock, valued at $16,995,267.64. The trade was a 23.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Michel Detheux sold 43,883 shares of the business’s stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $10.10, for a total transaction of $443,218.30. Following the completion of the transaction, the chief executive officer directly owned 135,903 shares of the company’s stock, valued at approximately $1,372,620.30. This represents a 24.41% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 1,939,307 shares of company stock worth $16,202,116. Corporate insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On iTeos Therapeutics

A number of institutional investors have recently bought and sold shares of ITOS. Strs Ohio purchased a new stake in iTeos Therapeutics in the first quarter valued at approximately $31,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in iTeos Therapeutics in the fourth quarter valued at approximately $42,000. CWM LLC grew its holdings in iTeos Therapeutics by 428.7% in the first quarter. CWM LLC now owns 8,554 shares of the company’s stock valued at $51,000 after purchasing an additional 6,936 shares during the period. Paloma Partners Management Co purchased a new stake in iTeos Therapeutics in the first quarter valued at approximately $65,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in iTeos Therapeutics in the first quarter valued at approximately $67,000. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

iTeos Therapeutics Price Performance

ITOS stock opened at $10.17 on Thursday. iTeos Therapeutics has a 1-year low of $4.80 and a 1-year high of $18.13. The company has a market capitalization of $389.21 million, a price-to-earnings ratio of -3.35 and a beta of 1.49. The business has a 50 day simple moving average of $8.98 and a two-hundred day simple moving average of $7.73.

iTeos Therapeutics (NASDAQ:ITOS) last issued its earnings results on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.14. Sell-side analysts anticipate that iTeos Therapeutics will post -3.49 EPS for the current fiscal year.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.